Martine E.D. Chamuleau

Author

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

M Chamuleau, M E Chamuleau, M E D Chamuleau, M. Chamuleau, M. E. Chamuleau, M. E. D. Chamuleau, M. E.D Chamuleau, M. E.D. Chamuleau, M.E. Chamuleau, M.E.D. Chamuleau

225

Publications

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam Erasmus MC Cancer Institute Amsterdam University Medical Centers University Medical Center Utrecht University of Amsterdam

About

Martine E.D. Chamuleau is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	21	1.1K
2	Immunology	15	19	736
3	Health Sciences	6	6	288
4	Cell Biology	6	6	134
5	Cellular Therapies	1	1	21

Martine E.D. Chamuleau

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Martin Hutchings, Rogier Mous, Michael Roost Clausen, The Lancet Subcutaneous EpcoritamabLymphoid NeoplasiaDose EscalationMedicineDermatology	2021	315
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Blood	2019	133
A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex Rogier Q. Hintzen, Rolien de Jong, C. Erik Hack, The Journal of Immunology	1991	126
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli, The Lancet Haematology Lymphoid NeoplasiaMedicineImmunologyFollicular LymphomaPathology	2018	112
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study Kim Linton, Umberto Vitolo, Wojciech Jurczak, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyRefractory Follicular Lymphoma	2024	111
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, Corine J. Hess, Haematologica Mixed-phenotype Acute LeukemiaImmunologyPathologyHigh IndoImmunotherapy	2008	99
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Blood Cancer Journal	2021	94
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment Theresia M. Westers, Canan Alhan, Martine E.D. Chamuleau, Blood	2009	91
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, C. J. Hess, Haematologica Mixed-phenotype Acute LeukemiaImmunologyPathologyHigh IndoImmunotherapy	2008	85
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome Martine E.D. Chamuleau, Theresia M. Westers, L. van Dreunen, Haematologica	2009	70

Page 1